Path Mental Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health provider marketplace matching patients with therapists and psychiatrists accepting insurance; San Francisco-based; handles insurance verification, credentialing, and administrative overhead for connecting patients to in-network mental health providers.
About
Path Mental Health is a San Francisco-based mental health platform that matches patients with therapists, psychologists, and psychiatrists who accept insurance, addressing the core access barrier in mental healthcare. Path handles the insurance verification, paperwork, and administrative overhead of connecting patients to in-network mental health providers, offering both individual therapy and medication management services. The platform targets the large population of individuals who want to use their health insurance for mental health care but struggle to find providers who are accepting new patients and take their specific insurance plan. Path works with major commercial insurers and provides access to licensed providers via telehealth and in-person sessions depending on location. Founded in 2019, Path raised over $120M from investors including Andreessen Horowitz and Foresite Capital. The company competes with Alma, Headway, and Grow Therapy in the therapist network and patient matching market.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.